Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxime Dougados

Showing results (441-450 of 600) with videos related to

Pageof 60
Sort By:
The Journal of Rheumatology|August 17, 2012
Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of RheumatologyDaniel Wendling, Maxime Dougados, Francis Berenbaum, et al.
Annals of the Rheumatic Diseases|February 9, 2020
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritisAlexandre Sepriano, Andreas Kerschbaumer, Josef S Smolen, et al.
Annals of the Rheumatic Diseases|March 12, 2017
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritisJackie L Nam, Kaoru Takase-Minegishi, Sofia Ramiro, et al.
Arthritis and Rheumatism|December 1, 2007
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysisEdward Keystone, Roy Fleischmann, Paul Emery, et al.
Annals of the Rheumatic Diseases|February 9, 2020
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritisAndreas Kerschbaumer, Alexandre Sepriano, Josef S Smolen, et al.
RMD Open|December 10, 2016
What is the reliability of non-trained investigators in recognising structural MRI lesions of sacroiliac joints in patients with recent inflammatory back pain? Results of the DESIR cohortCharlotte Jacquemin, Roxana Rubio Vargas, Rosaline van den Berg, et al.
Joint Bone Spine|September 24, 2018
Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensusLaure Gossec, Anna Molto, Xavier Romand, et al.
Rheumatology (Oxford, England)|September 29, 2017
Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATEJacques Morel, Arnaud Constantin, Gabriel Baron, et al.
Rheumatology (Oxford, England)|August 28, 2012
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb studyMichael E Weinblatt, Roy Fleischmann, Tom W J Huizinga, et al.
Clinical and Experimental Rheumatology|July 27, 2022
Clinical significance of a self-reported familial occurrence of rheumatoid arthritis among patients with recent-onset arthritis: data from the ESPOIR cohortDewi Guellec, Guillermo Carvajal-Alegria, Claire Daïen, et al.
Pageof 60

Showing results (441-450 of 600) with videos related to

Sort By:
Pageof 60
The Journal of Rheumatology|August 17, 2012
Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of RheumatologyDaniel Wendling, Maxime Dougados, Francis Berenbaum, et al.
Annals of the Rheumatic Diseases|February 9, 2020
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritisAlexandre Sepriano, Andreas Kerschbaumer, Josef S Smolen, et al.
Annals of the Rheumatic Diseases|March 12, 2017
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritisJackie L Nam, Kaoru Takase-Minegishi, Sofia Ramiro, et al.
Arthritis and Rheumatism|December 1, 2007
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysisEdward Keystone, Roy Fleischmann, Paul Emery, et al.
Annals of the Rheumatic Diseases|February 9, 2020
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritisAndreas Kerschbaumer, Alexandre Sepriano, Josef S Smolen, et al.
RMD Open|December 10, 2016
What is the reliability of non-trained investigators in recognising structural MRI lesions of sacroiliac joints in patients with recent inflammatory back pain? Results of the DESIR cohortCharlotte Jacquemin, Roxana Rubio Vargas, Rosaline van den Berg, et al.
Joint Bone Spine|September 24, 2018
Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensusLaure Gossec, Anna Molto, Xavier Romand, et al.
Rheumatology (Oxford, England)|September 29, 2017
Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATEJacques Morel, Arnaud Constantin, Gabriel Baron, et al.
Rheumatology (Oxford, England)|August 28, 2012
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb studyMichael E Weinblatt, Roy Fleischmann, Tom W J Huizinga, et al.
Clinical and Experimental Rheumatology|July 27, 2022
Clinical significance of a self-reported familial occurrence of rheumatoid arthritis among patients with recent-onset arthritis: data from the ESPOIR cohortDewi Guellec, Guillermo Carvajal-Alegria, Claire Daïen, et al.
Pageof 60